Q3 2026 Sun Pharmaceutical Industries Ltd Earnings Call Transcript

Jan 31, 2026 / 01:00 PM GMT

Transcript

Key Points

Positve

Sun Pharmaceuticals Industries Ltd (BOM:524715) reported a 15.1% increase in sales for Q3 FY26 compared to Q3 FY25, driven by underlying business growth and milestone income.
The company's gross margin improved to 81% due to a better product mix.
EBITDA for the quarter increased by 23.4% year-over-year, with EBITDA margins rising to 31.9%.
The India business recorded a 16.2% growth in sales, with Sun Pharma maintaining its number one position in the Indian pharmaceutical market.
The company launched 12 new products in India during the quarter, indicating strong product development and market penetration.

Negative

The US business saw only a marginal increase of 0.6% in sales, with growth in Innovative Medicines offset by lower sales in the generic business due to increased competition.
An exceptional charge of INR4,895 million was recorded due to wage court gratuity and additional provisions for GxMDL final settlement.
The effective tax rate increased to 24.3% from 14.7% in the previous year, impacting net profit growth.
R&D spend on the innovative portfolio has been reducing over the past few quarters, raising concerns about future pipeline development.
The generic business in the US experienced a decline due to specific competition for certain products, affecting overall sales performance.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

SUN.NS - Sun Pharmaceutical Industries Ltd
Q3 2026 Sun Pharmaceutical Industries Ltd Earnings Call
Jan 31, 2026 / 01:00PM GMT

=====================
Conference Call Participants
=====================
* Abhishek Sharma
* Jayashree Satagopan
* Kirti Ganorkar
* Richard Ascroft
* Aalok Shanghvi
* Dilip Shanghvi
* Rishi Parekh
* Tushar Manudhane
Motilal Oswal Securities Ltd - Analyst
* Damayanti Kerai
* Neha Manpuria
Bofa Merrill Lynch Asset Holdings Inc - Analyst
* Bino Pathiparampil
Elara Securities (India) Pvt Ltd - Analyst
* Girish Bakhru
* Vishal Manchanda
* Kunal Dhamesha
Macquarie Group Ltd - Analyst
* Shashank Krishnakumar
* Vivek Agrawal
* Foram Parekh
* Abdulkader Puranwala

=====================
Presentation
--------------------------------------------------------------------------------
Operator [1]
--------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.